nerve-cell-2213009_960_720

Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders

Ella Day | July 14, 2025 | News story | Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions 

Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS). This intends to create new treatments for neurodegenerative and other central nervous system disorders, and marks a milestone in both companies’ expansion in targeted delivery and CNS indications.

The partnership will combine Vect-Horus’ delivery technology platform, VECTrans, a delivery system specialising in shuttling therapeutic or imaging payloads across biological barriers, with Secarna’s proprietary OligoCreator platform for oligonucleotide discovery.

Vect-Horus develops vectors that target and deliver therapeutics to imaging agents or organs, including the brain and tumours. Secarna works on oligonucleotide therapeutics, delivering these novel therapeutics to the cells, organs or tissues where they are needed.

Advertisement

“This partnership brings together two complementary platforms to address one of the most challenging aspects of CNS drug development – effective, targeted and systemic delivery across the BBB,” said Konstantin Petropoulos, CEO of Secarna.

Alexandre Tokay, CEO of Vect-Horus, said: “By combining our technologies, we aim to advance RNA-targeted therapies for CNS disorders and bring forward innovative treatment options for patients who have limited and ineffective treatment options.”

Ella Day

14/7/25


The Pharmafile Brief

This article featured in: August 2025 – The Pharmafile Brief

Related Content

MetP Pharma releases positive data on intranasal semaglutide administration

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …

handshake_2

Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement

Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and …

Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases

Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part …

The Gateway to Local Adoption Series

Latest content